Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "cancers"

349 News Found

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Drug Approval | December 20, 2022

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit


Mylab receives approval for HPV RT-PCR test for cervical cancers
Clinical Trials | September 28, 2022

Mylab receives approval for HPV RT-PCR test for cervical cancers

‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.


Next-gen immunotherapy drug shows promise in several advanced-stage cancers
Biotech | May 27, 2022

Next-gen immunotherapy drug shows promise in several advanced-stage cancers

Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells


Biological Dynamics study demonstrates detection of early-stage cancers
Biotech | March 21, 2022

Biological Dynamics study demonstrates detection of early-stage cancers

In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis


Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers
Public Health | March 04, 2022

Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers

To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers


Merck showcases potential for several cancers, MS and lupus
News | November 22, 2021

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline


Research demonstrates Hoth Therapeutics HT-KIT for mast cell cancers reduces size and spread
Drug Approval | August 12, 2021

Research demonstrates Hoth Therapeutics HT-KIT for mast cell cancers reduces size and spread

Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm


Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening
News | February 07, 2026

Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening

Hologic has been at the forefront of cervical cancer screening for decades


Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy
News | February 04, 2026

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway